NCT04699617 is a NA clinical trial of Dolphin 2.0 in Parkinson Disease, sponsored by Campus Neurológico Sénior.

Who is sponsoring NCT04699617?

NCT04699617 is sponsored by Campus Neurológico Sénior.

What drugs are being tested in NCT04699617?

Interventions in NCT04699617: Dolphin 2.0.

What condition does NCT04699617 study?

NCT04699617 studies Parkinson Disease.

Is NCT04699617 still recruiting?

NCT04699617 is currently completed. Last updated 16 August 2023.

Last reviewed 2023-08-16 · How we verify

NCT04699617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients

Completed NA Last updated 16 August 2023

What this trial tests

NA trial testing Dolphin 2.0 in Parkinson Disease in 30 participants. Completed in 28 February 2022.

Timeline

28 December 2020

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Campus Neurológico Sénior
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	28 December 2020
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	1 location across Portugal

Drugs / interventions tested

Dolphin 2.0

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Campus Neurológico Sénior

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures (dolphin, orca, axolotl). Video games lead to high levels of motivation and arousal, provide immediate feedback and playback, provide explicit reward and implicit success, and titrate difficulty levels. This encourages the practice of exercise, being an important complement to physiotherapy sessions. The main goal of this study is to evaluate the feasibility, safety and efficacy of an immersive virtual reality software (Dolphin, 2.0) in Parkinson's disease symptomatic control, in a two-arm, randomized, single-blind (blind rater for primary and secondary outcomes), delayed-start feasibility and efficacy trial.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.
Ernst M, Folkerts AK, Gollan R, Lieker E, et al · · 2023 · cited 110× · PMID 36602886 · DOI 10.1002/14651858.cd013856.pub2
Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.
Ernst M, Folkerts AK, Gollan R, Lieker E, et al · · 2024 · cited 37× · PMID 38588457 · DOI 10.1002/14651858.cd013856.pub3
Combining immersive exergaming with physiotherapy in a specialized intensive Parkinson's disease rehabilitation program: a randomized controlled trial.
Pimenta Silva D, Bouça-Machado R, Pona-Ferreira F, Lobo T, et al · · 2025 · cited 1× · PMID 40500714 · DOI 10.1186/s12984-025-01640-w

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Campus Neurológico Sénior trials

Trials by the same sponsor.

NCT06052930 — Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease · NA · completed
NCT03891069 — Feasibility of the AHA Exergame System in Parkinson's Disease Patients · NA · completed
NCT03123601 — Feasibility of Risk Sign Displays to Prevent Falls, Dehydration and Pulmonary Aspiration in Nursing Homes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04699617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Campus Neurológico Sénior
Last refreshed: 16 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04699617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing